Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
November 14th 2022Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Read More
NCPA CEO: Express Scripts Is Limiting, Restricting Veterans’ Access to Health Care
November 11th 2022This Veteran’s Day, NCPA CEO B. Douglas Hoey, PharmD, MBA, discusses the implications of Express Scripts’ elimination of the pharmacy of choice option for TRICARE beneficiaries in their contract with the Department of Defense.
Watch